NCT02063607已完成1 期
The Phase 1a/1b Study of Safety, Pharmacokinetics, Pharmacodynamics of Peglamda (Peginterferon Lamda 1) on Healthy Volunteers and the Preliminary Evaluation of Peglamda and Hepasig (Ribavirin) Treatment's Effects on Chronic Hepatitis C Patients
Nanogen Pharmaceutical Biotechnology Joint Stock Company2 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2013年12月最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 60
- 试验地点
- 2
- 主要终点
- Area Under the Concentration-Time Curve (AUC 0-336)
研究概览
简要总结
This is an open label, dose ranging, phase1a/1b clinical trial to study the safety, Pharmacokinetics and Pharmacodynamics of Peglamda 60, 120, 180 and 240 mcg in healthy volunteers and antiviral activity of once weekly Peglamda administration in combination with daily Ribavirin in Hepatitis C naive patients up to 4 weeks period. The objective of the study to establish safety, PK/PD data on healthy subjects and preliminary efficacy and safety in Hepatitis C naive patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Phase 1a: The subjects who are willing to participate in Phase 1a study must meet ALL of the following inclusion criteria:
- •Volunteers (male and female) between the ages of 18-45
- •Women have a negative pregnancy test result at the time of study.
- •Clinical examination and result laboratory for 7 days before starting the trial must be inside the normal range.
- •Currently not following any treatment regimen (except for using the oral contraceptive).
- •Body mass index is between the range and / or not 25% difference compared to the normal BMI (Appendix 6).
- •Be able to comply with protocol and exchange information effectively with the researchers, agree on the written informed consent to participate in the clinical trial
- •Phase 1b: Subjects willing to participate into the phase 1b study must meet ALL of the following inclusion criteria:
- •Patients with chronic hepatitis C (male and female).
- •Ages between 18 - 65 years old.
- •Female patient (or female partners of the male patients) with negative pregnancy test results and/or apply effective contraception if still having sex during the study and for 6 months after using the last dose of Ribavirin.
- •No previous treatment with IFN or IFN treatment with rapid viral response or already have completely viral response but leave the treatment early.
- •HCV-RNA levels in serum > 80 IU / mL.
- •The haematological and biochemical (except ALT / AST) parameters must be within normal limits.
- •Body weight in the normal range of 25% difference compared to the normal BMI (Appendix 6)
- •Be able to comply with protocol and exchange information effectively with the researchers, agree on the written informed consent to participate in the clinical trial
排除标准
- •Phase 1a: Subjects with at least 1 of the following exclusion criteria are considered ineligible to participate in Phase 1a study:
- •With a history of drug abuse, alcohol or drug using within 1 year before taking part in the clinical trial. AUDIT-C scale (WHO) will be used to assess the use of alcohol. The score ≥ 4 in men or ≥ 3 in women are considered as alcoholics.
- •History of depression
- •History of chronic diseases related to the respiratory system, cardiovascular, gastrointestinal, malignant disease affecting to the function of the organ systems. Having any interferon or antiviral therapy within 4 months before the trial
- •Participate in any clinical trial within 3 months prior the testing
- •Use of any drug in the last period of relatively positive test which last approximately 6 times the half-life of the drug.
- •Blood donor with more than 400 mL of blood within 3 months prior the testing
- •Influenza infection or cold symptoms within 2 weeks before the trial
- •Having positive tests of HBV, HCV or HIV
- •Breastfeeding women
- •Phase 1b: Subjects with at least 1 of the following exclusion criteria are considered ineligible to participate in Phase 1b study:
- •Co-infection with hepatitis B and/or HIV.
- •Hepatic Impairment
- •Positive tests with antibody of Peginterferon lambda 1 and Peginterferon alpha 2a.
- •History of chronic diseases related to the respiratory system, cardiovascular, gastrointestinal, malignant disease affecting to the function of the organ systems.
- •A history of immune disorders (eg, inflammatory bowel disease, hemorrhagic thrombocythemia, lupus erythematosus, autoimmune hemolytic anemia, autoimmune disease, scleroderma, severe psoriasis, arthritis rheumatoid ...)
- •A history of severe mental illness, especially depression, especially the serious neurological condition determined as depression or serious psychological disorders, suicidal intention, or being hospitalized for mental illness, or having 1 phase of impaired function due to neuropathy.
- •A history of severe epilepsy or using antiepileptic drugs.
- •A history of using anti-cancer agents (including radiation therapy) or immunotherapy (including systematic corticosteroids) within 6 months before using the first testing dose or the patient may be in need of this treatment during the trial
- •History of organ transplants with the presence of the graft function.
- •Evidence of alcohol or drugs abuse within 1 year before the trial. AUDIT scale - C will be used to assess the use of alcohol. The score ≥ 4 in men or ≥ 3 in women are considered as alcoholics
- •History or evidence of severe disease or any other condition based on the investigator assessment that the subject may not be suitable for this study.
- •Breastfeeding women.
结局指标
主要结局
Area Under the Concentration-Time Curve (AUC 0-336)
时间窗: 0, 6, 12, 24, 36, 48, 72, 96, 120, 144, 168, 216, 264 and 336 hours
Percentage of Patients achieving Rapid Virological Response (RVR)
时间窗: 4 weeks
次要结局
- Number of subjects with incidence of adverse events(15 days)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
Open Label, Dose-finding, Pharmacokinetics, Safety and Tolerability Study of Oritavancin in Pediatric Participants With Suspected or Confirmed Bacterial InfectionsNCT02134301Melinta Therapeutics, LLC41
已完成
1 期
A Study Evaluating the Safety, Tolerability, and Initial Efficacy of Recombinant Human Anti-cluster Differentiation Antigen 47 (CD47) Monoclonal Antibody Injection (IBI188) in Patients With Advanced Malignant Tumors and LymphomasAdvanced MalignanciesNCT03763149Innovent Biologics (Suzhou) Co. Ltd.20
招募中
1 期
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.Non Hodgkin LymphomaT-cell-prolymphocytic LeukemiaAcute Lymphocytic LeukemiaMyeodysplastic SyndromeMyelodysplastic/Myeloproliferative NeoplasmMultiple MyelomaAcute Myeloid LeukemiaChronic Lymphocytic LeukemiaSmall Lymphocytic LymphomaChronic Myelomonocytic Leukemia-2Myelodysplastic Neoplasm in Blast PhaseMyelofibrosisRichter TransformationNCT04771572Newave Pharmaceutical Inc100
终止
1 期
A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley)Advanced CancerNCT02554812Pfizer409
已完成
1 期
The Safety and Tolerability of STSA-1002 Following Subcutaneous Injection in Healthy SubjectsAntineutrophil Cytoplasmic Antibody Associated VasculitisNCT05702983Staidson (Beijing) Biopharmaceuticals Co., Ltd20